{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T18:12:37Z","timestamp":1776795157968,"version":"3.51.2"},"reference-count":33,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2019,3,19]],"date-time":"2019-03-19T00:00:00Z","timestamp":1552953600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002888","name":"Beijing Municipal Commission of Education","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002888","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"DOI":"10.3389\/fphar.2019.00242","type":"journal-article","created":{"date-parts":[[2019,3,19]],"date-time":"2019-03-19T05:16:56Z","timestamp":1552972616000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":15,"title":["Sub-Acute Oral Toxicity of a Novel Derivative of Agomelatine in Rats in a Sex-Dependent Manner"],"prefix":"10.3389","volume":"10","author":[{"given":"Qiushi","family":"Yang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xuelin","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jingyi","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jie","family":"Xiong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pingxiang","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuhang","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Gu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ming","family":"Xue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zengliang","family":"Jin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaorong","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2019,3,19]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.etap.2018.05.021","article-title":"In vivo investigation on the chronic hepatotoxicity induced by sertraline.","volume":"61","author":"Almansour","year":"2018","journal-title":"Environ. Toxicol. Pharmacol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"121","DOI":"10.5505\/tjtes.2015.29499","article-title":"Beneficial effects of agomelatine in experimental model of sepsis-related acute kidney injury.","volume":"22","author":"Ba\u015fol","year":"2016","journal-title":"Ulus. Travma Acil Cerrahi Derg."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1847","DOI":"10.1053\/j.gastro.2004.10.012","article-title":"Assessing fibrosis without a liver biopsy: are we there yet?","volume":"127","author":"Bissell","year":"2004","journal-title":"Gastroenterology"},{"key":"B4","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.euroneuro.2015.11.003","article-title":"Behavioral and neurochemical characterization of TrkB-dependent mechanisms of agomelatine in glucocorticoid receptor-impaired mice.","volume":"26","author":"Boulle","year":"2016","journal-title":"Eur Neuropsychopharmacol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"2411","DOI":"10.1517\/14656566.2011.607812","article-title":"Agomelatine for the treatment of major depressive disorder.","volume":"12","author":"Carney","year":"2011","journal-title":"Expert Opin. Pharmacother."},{"key":"B6","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1017\/S1092852916000572","article-title":"Effect of agomelatine treatment on C-reactive protein levels in patients with major depressive disorder: an exploratory study in \u201creal-world,\u201d everyday clinical practice.","volume":"22","author":"De Berardis","year":"2017","journal-title":"CNS Spectr."},{"key":"B7","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1007\/s40263-018-0537-1","article-title":"Antidepressants and hepatotoxicity: a cohort study among 5 million individuals registered in the french national health insurance database.","volume":"32","author":"de Gage","year":"2018","journal-title":"CNS Drugs"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1007\/s11011-016-9874-9872","article-title":"Agomelatine reduces brain, kidney and liver oxidative stress but increases plasma cytokine production in the rats with chronic mild stress-induced depression.","volume":"31","author":"Demirda\u015f","year":"2016","journal-title":"Metab. Brain Dis."},{"key":"B9","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1080\/13543784.2017.1267727","article-title":"Investigational drugs for treating major depressive disorder.","volume":"26","author":"Dhir","year":"2017","journal-title":"Expert Opin. Investig. Drugs"},{"key":"B10","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1016\/j.biopha.2017.12.101","article-title":"Olive oil and leaf extract prevent fluoxetine-induced hepatotoxicity by attenuating oxidative stress, inflammation and apoptosis.","volume":"98","author":"Elgebaly","year":"2018","journal-title":"Biomed. Pharmacother."},{"key":"B11","year":"2009","journal-title":"Thymanax: EPAR-Public Assessment Report. 1-66"},{"key":"B12","year":"2017","journal-title":"ANNEX I Summary of Product Characteristics (UMA). 1-31"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1186\/s40303-015-0011-17","article-title":"A systematic review of agomelatine-induced liver injury.","volume":"3","author":"Freiesleben","year":"2015","journal-title":"J. Mol. Psychiatry"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1093\/ijnp\/pyv126","article-title":"Drug-induced liver injury during antidepressant treatment: results of AMSP, a drug surveillance program.","volume":"19","author":"Friedrich","year":"2016","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"694","DOI":"10.2174\/1389200215666140926155041","article-title":"Safety and tolerability of agomelatine: focus on hepatotoxicity.","volume":"15","author":"Gahr","year":"2014","journal-title":"Curr. Drug Metab."},{"key":"B16","doi-asserted-by":"publisher","first-page":"3604","DOI":"10.1111\/bph.12720","article-title":"Agomelatine: mechanism of action and pharmacological profile in relation to antidepressant properties.","volume":"171","author":"Guardiola-Lemaitre","year":"2014","journal-title":"Br. J. Pharmacol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"1987","DOI":"10.1021\/acs.chemrestox.5b00201","article-title":"Inhibition of MDR3 activity in human hepatocytes by drugs associated with liver injury.","volume":"28","author":"He","year":"2015","journal-title":"Chem. Res. Toxicol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1016\/S2221-1691(12)60075-60076","article-title":"Evaluation of antihepatotoxic potential of Solanum xanthocarpum fruit extract against antitubercular drugs induced hepatopathy in experimental rodents.","volume":"2","author":"Hussain","year":"2012","journal-title":"Asian Pac. J. Trop. Biomed."},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1259\/bjr.20150716","article-title":"A novel approach to contrast-induced nephrotoxicity: the melatonergic agent agomelatine.","volume":"89","author":"Karaman","year":"2016","journal-title":"Br. J. Radiol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/ijnp\/pyw003","article-title":"Agomelatine increases BDNF serum levels in depressed patients in correlation with the improvement of depressive symptoms.","volume":"19","author":"Martinotti","year":"2016","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.2147\/NDT.S129793","article-title":"Agomelatine in the treatment of mild-to-moderate depression in patients with cardiovascular disease: results of the national multicenter observational study PULSE.","volume":"13","author":"Medvedev","year":"2017","journal-title":"Neuropsychiatr. Dis. Treat."},{"key":"B22","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1124\/jpet.103.051797","article-title":"The novel melatonin agonist agomelatine (S20098) is an antagonist at 5-hydroxytryptamine2C receptors, blockade of which enhances the activity of frontocortical dopaminergic and adrenergic pathways.","volume":"306","author":"Millan","year":"2003","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2202-14-75","article-title":"Chronic treatment with agomelatine or venlafaxine reduces depolarization-evoked glutamate release from hippocampal synaptosomes.","volume":"14","author":"Milanese","year":"2013","journal-title":"BMC Neurosci."},{"key":"B24","doi-asserted-by":"publisher","first-page":"1645","DOI":"10.1016\/j.euroneuro.2013.03.008","article-title":"Modulation of the inflammatory response in rats chronically treated with the antidepressant agomelatine.","volume":"23","author":"Molteni","year":"2013","journal-title":"Eur. Neuropsychopharmacol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1097\/01.yic.0000137184.64610.c8","article-title":"Absence of discontinuation symptoms with agomelatine and occurrence of discontinuation symptoms with paroxetine: a randomized, double-blind, placebo-controlled discontinuation study.","volume":"19","author":"Montgomery","year":"2004","journal-title":"Int. Clin. Psychopharmacol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"207","DOI":"10.2174\/1574886311308030011","article-title":"Liver injury associated with antidepressants.","volume":"8","author":"Park","year":"2013","journal-title":"Curr. Drug Saf."},{"key":"B27","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1007\/s40263-016-0351-356","article-title":"Characterisation of agomelatine-induced increase in liver enzymes: frequency and risk factors determined from a pooled analysis of 7605 treated patients.","volume":"30","author":"Perlemuter","year":"2016","journal-title":"CNS Drugs"},{"key":"B28","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.13748\/j.cnki.issn1007-7693.2016.08.024","article-title":"Clinical effective rate of four clinical commonly used antidepressants with different therapeutic mechanisms in depression disorder in china: a meta-analysis of single rate.","volume":"33","author":"Qiang","year":"2016","journal-title":"Chin. J. Mod. Appl. Pharm."},{"key":"B29","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1017\/S1461145711000356","article-title":"Beneficial behavioural and neurogenic effects of agomelatine in a model of depression\/anxiety.","volume":"15","author":"Rainer","year":"2012","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1080\/15622975.2017.1298839","article-title":"Genome-wide analysis of LPS-induced inflammatory response in the rat ventral hippocampus: modulatory activity of the antidepressant agomelatine.","volume":"19","author":"Rossetti","year":"2018","journal-title":"World J. Biol. Psychiatry"},{"key":"B31","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1176\/appi.ajp.2013.13050709","article-title":"Antidepressant-induced liver injury: a review for clinicians.","volume":"171","author":"Voican","year":"2014","journal-title":"Am. J. Psychiatry"},{"key":"B32","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1097\/JCP.0b013e31822347d9","article-title":"Duloxetine for depression and the incidence of hepatic events in adults.","volume":"31","author":"Xue","year":"2011","journal-title":"J. Clin. Psychopharmacol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1055\/s-0042-112366","article-title":"Agomelatine and transient elevation of creatine phosphokinase.","volume":"66","author":"Zormann","year":"2016","journal-title":"Drug Res."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fphar.2019.00242\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,3,19]],"date-time":"2019-03-19T05:16:58Z","timestamp":1552972618000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fphar.2019.00242\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3,19]]},"references-count":33,"alternative-id":["10.3389\/fphar.2019.00242"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2019.00242","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,3,19]]},"article-number":"242"}}